BioSpecifics Technologies Corp.
BSTC
BSTC was delisted on the 1st of December, 2020.
112 hedge funds and large institutions have $263M invested in BioSpecifics Technologies Corp. in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 16 closing their positions.
7% more capital invested
Capital invested by funds: $247M → $263M (+$16.1M)
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
2% less funds holding
Funds holding: 114 → 112 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$5.64M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$3.43M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$2.25M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.87M |
| 5 |
Aviva
London,
United Kingdom
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.1M |
| 2 |
RC
Roubaix Capital
Denver,
Colorado
|
-$2.09M |
| 3 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$1.88M |
| 4 |
RA
Royce & Associates
New York
|
-$1.64M |
| 5 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$1.47M |
BSTC Hedge Fund Activity: Q4 2019 in Review
112 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q4 2019, worth a combined $263M — up 6.5% from $247M a quarter earlier.
Fund positioning in BSTC was balanced in Q4 2019: 16 funds opened new positions, 16 closed out, 39 added to existing stakes and 36 trimmed.
The largest buyer was Russell Investments Group, adding an estimated $5.64M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $6.1M sold.
- 112 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q4 2019, down from 114 in Q3 2019.
- Funds reported $263M of BioSpecifics Technologies Corp. stock for Q4 2019, up 6.5% quarter-over-quarter.
- 16 funds opened new BioSpecifics Technologies Corp. positions in Q4 2019 and 16 closed out, a net change of 0 holders.
- The largest BioSpecifics Technologies Corp. buyer in Q4 2019 was Russell Investments Group, an estimated $5.64M added.
- The largest BioSpecifics Technologies Corp. seller in Q4 2019 was Acadian Asset Management, an estimated $6.1M sold.
Based on aggregated 13F filings for Q4 2019.